Copper in diseases and treatments, and copper-based anticancer strategies

Medicinal Research Reviews

Volumn 30, Issue 4, 2010, Pages 708-749

  Tisato, Francesco ^a   Marzano, Cristina ^b   Porchia, Marina ^a   Pellei, Maura ^c   Santini, Carlo ^c  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Angiogenesis; Anticancer metallodrugs; Copper; Copper chelation; Menkes and Wilson diseases

Indexed keywords

APOPTOSIS INDUCING FACTOR; ASCORBATE OXIDASE; CHELATING AGENT; COPPER; COPPER COMPLEX; COPPER DERIVATIVE; CYTOCHROME C OXIDASE; FREE RADICAL; HISTIDINE COPPER; MONOPHENOL MONOOXYGENASE; PROTEASOME INHIBITOR; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BREAST CANCER; BREATHING; CHELATION THERAPY; COLON CANCER; COPPER DEFICIENCY; COPPER METABOLISM; CREUTZFELDT JAKOB DISEASE; DNA SYNTHESIS; ENERGY METABOLISM; HUMAN; LUNG CANCER; MENKES SYNDROME; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PROSTATE CANCER; REVIEW; WILSON DISEASE; ANIMAL; CHEMISTRY; HEPATOLENTICULAR DEGENERATION; MENKES KINKY HAIR SYNDROME; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; MENKES KINKY HAIR SYNDROME; NEOPLASMS;

EID: 77953841809     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20174     Document Type: Review

References (231)

1. Linder MC. Biochemistry of copper. New York: Plenum Press; 1991.
2. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990;186:1-85. (Pubitemid 20279941)
3. Aust SD, Morehouse LA, Thomas CE. Role of metals in oxygen radical reactions. J Free Radic Biol Med 1985;1:3-25.
4. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase. Science 1999;284:805-808. (Pubitemid 29291346)
5. Turnlund JR, Keyes WR, Anderson HL, Acord LL. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope copper-65. Am J Clin Nutr 1989;49:870-878. (Pubitemid 19139791)
6. Wang T, Guo ZJ. Copper in medicine: Homeostasis, chelation therapy and antitumor drug design. Curr Med Chem 2006;13:525-537.
7. Bull PC, Cox DW. Wilson disease and Menkes disease: New handles on heavy-metal transport. Trends Genet 1994;10:246-252.
8. Turski ML, Thiele DJ. New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem 2009;284:717-721.
9. Daniel KG, Harbach RH, Guida WC, Dou QP. Copper storage diseases: Menkes, Wilson's, and cancer. Front Biosci 2004;9:2652-2662.
10. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000;4:184-191.
11. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. Br J Pharmacol 2005;146:1041-1059. (Pubitemid 41786957)
12. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem 2001;276:44284-44296. (Pubitemid 37384003)
13. Requena JR, Groth D, Legname G, Stadtman ER, Prusiner SB, Levine RL. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc Natl Acad Sci USA 2001;98:7170-7175.
14. Gaggelli E, Bernardi F, Molteni E, Pogni R, Valensin D, Valensin G, Remelli M, Luczkowski M, Kozlowski H. Interaction of the human prion PrP(106-126) sequence with copper(II), manganese(II), and zinc(II): NMR and EPR studies. J Am Chem Soc 2005;127:996-1006.
15. Klewpatinond M, Davies P, Bowen S, Brown DR, Viles JH. Deconvoluting the Cu2+binding modes of full-length prion protein. J Biol Chem 2008;283:1870-1881.
16. 2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease. Biochim Biophys Acta, Proteins Proteomics 2006;1764:246-256.
17. Karr JW, Szalai VA. Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the alzheimer's disease amyloid-beta peptide. Biochemistry 2008;47:5006-5016.
18. Molina-Holgado F, Hider RC, Gaeta A, Williams R, Francis P. Metals ions and neurodegeneration. Biometals 2007;20:639-654.
19. Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 2004;67:1139-1151. (Pubitemid 38296793)
20. Marzano C, Pellei M, Tisato F, Santini C. Copper complexes as anticancer agents. Anti-Canc Agents in Med Chem 2009;9:185-211.
21. Popova TV, Aksenova NV. Complexes of copper in unstable oxidation states. Russ J Coord Chem 2003;29:743-765.
22. Greenwood NN, Earnshaw A. Chemistry of the elements. 2nd ed. Oxford: Butterworth-Heinemann; 1998. pp 1173-1200.
23. Conry R. Copper: Inorganic & coordination chemistry. In: King R, editor. Encyclopedia of inorganic chemistry. Chichester, United Kingdom: John Wiley & Sons Ltd; 2005.
24. Cotton FA, Wilkinson G, Murillo CA, Bochmann M. Copper: Group 11. Advanced inorganic chemistry. 6th ed. New York: Wiley Interscience; 1999. pp 854-876.
25. Mukherjee R. Copper. In: McCleverty JA, Meyer TJ, editors. Comprehensive coordination chemistry II - from biology to nanotechnology. Vol. 6. Oxford (UK): Elsevier Ltd.; 2004. pp 747-910.
26. 2M [M5copper(I), silver(I)] monomeric complexes with the coordination number of 1. Angew Chem 1988;100:409-410.
27. Murphy B, Hathaway B. The stereochemistry of the copper(II) ion in the solid-state-some recent perspectives linking the Jahn-Teller effect, vibronic coupling, structure correlation analysis, structural pathways and comparative X-ray crystallography. Coord Chem Rev 2003;243:237-262.
28. Kitajima N, Moro-oka Y. Copper-dioxygen complexes. Inorganic and Bioinorganic Perspectives. Chem Rev 1994;94:737-757.
29. Kaim W, Rall J. Copper - A "modern" bioelement. Angew Chem Int Ed Engl 1996;35:43-60.
30. Ochiai E. Iron versus copper. II. Principles and applications in bioinorganic chemistry. J Chem Educ 1986;63:942-944.
31. Frausto Da Silva JJR, Williams RJP. The biological chemistry of elements. The inorganic chemistry of life: Oxford: Clarendon Press; 1994.
32. Dennison C. Investigating the structure and function of cupredoxins. Coord Chem Rev 2005;249:3025-3054.
33. Solomon EI, Baldwin MJ, Lowery MD. Electronic structures of active sites in copper proteins: Contributions to reactivity. Chem Rev 1992;92:521-542.
34. Klinman JP. Mechanisms whereby mononuclear copper proteins functionalize organic substrates. Chem Rev 1996;96:2541-2561.
35. Fontecave M, Pierre J-L. Oxidations by copper metalloenzymes and some biomimetic approaches. Coord Chem Rev 1998;170:125-140. (Pubitemid 128094310)
36. Roat-Malone RM. Bioinorganic chemistry. Hoboken, NJ: Wiley; 2002. pp 187-230.
37. Gray HB, Malmstrom BG, Williams RJP. Copper coordination in blue proteins. J Biol Inorg Chem 2000;5:551-559.
38. Inoue T, Nishio N, Suzuki S, Kataoka K, Kohzuma T, Kai Y. Crystal structure determinations of oxidized and reduced pseudoazurins from Achromobacter cycloclastes. Concerted movement of copper site in redox forms with the rearrangement of hydrogen bond at a remote histidine. J Biol Chem 1999;274:17845-17852. (Pubitemid 29283306)
39. Crane BR, Di Bilio AJ, Winkler JR, Gray HB. Electron tunneling in single crystals of Pseudomonas aeruginosa azurins. J Am Chem Soc 2001;123:11623-11631.
40. Williams RJP. Energized (entatic) states of groups and of secondary structures in proteins and metalloproteins. Eur J Biochem 1995;234:363-381.
41. Malmstrom BG. Rack-induced bonding in blue-copper proteins. Eur J Biochem 1994;223:711-718.
42. Solomon EI, Szilagyi RK, DeBeer George S, Basumallick L. Electronic structures of metal sites in proteins and models: Contributions to function in blue copper proteins. Chem Rev 2004;104:419-458.
43. Ryde U, Olsson MHM, Roos BO, Borin AC. A theoretical study of the copper-cysteine bond in blue copper proteins. Theor Chem Acc 2001;105:452-462. (Pubitemid 33270993)
44. Chaka G, Sonnenberg Jason L, Schlegel HB, Heeg Mary J, Jaeger G, Nelson Timothy J, Ochrymowycz LA, Rorabacher DB. A definitive example of a geometric "entatic state" effect: Electron-transfer kinetics for a copper(II/I) complex involving A quinquedentate macrocyclic trithiaether-bipyridine ligand. J Am Chem Soc 2007;129:5217-5227.
45. Maryon EB, Molloy SA, Zimnicka AM, Kaplan JH. Copper entry into human cells: Progress and unanswered questions. Biometals 2007;20:355-364.
46. Milne DB. Copper intake and assessment of copper status. Am J Clin Nutr 1998;67:1041S-1045S.
47. Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother 2003;57:386-398. (Pubitemid 37494714)
48. Linder MC, Wooten L, Cerveza P, Cotton S, Shulze R, Lomeli N. Copper transport. Am J Clin Nutr 1998;67:965S-971S.
49. Dancis A, Yuan DS, Haile D, Askwith C, Eide D, Moehle C, Kaplan J, Klausner RD. Molecular characterization of a copper transport protein in S. cerevisiae: An unexpected role for copper in iron transport. Cell 1994;76:393-402. (Pubitemid 124000739)
50. Puig S, Lee J, Lau M, Thiele DJ. Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J Biol Chem 2002;277:26021-26030. (Pubitemid 34967084)
51. Aller SG, Unger VM. Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture. Proc Natl Acad Sci USA 2006;103:3627-3632.
52. Lee J, Pena MMO, Nose Y, Thiele DJ. Biochemical characterization of the human copper transporter Ctr1. J Biol Chem 2002;277:4380-4387. (Pubitemid 34968704)
53. Eisses JF, Stasser JP, Ralle M, Kaplan JH, Blackburn NJ. Domains I and III of the human copper chaperone for superoxide dismutase interact via a cysteine-bridged dicopper(I) cluster. Biochemistry 2000;39:7337-7342.
54. Huffman DL, O'Halloran TV. Function, structure, and mechanism of intracellular copper trafficking proteins. Annu Rev Biochem 2001;70:677-701.
55. Prohaska JR, Gybina AA. Intracellular copper transport in mammals. J Nutr 2004;134:1003-1006.
56. Finney LA, O'Halloran TV. Transition Metal Speciation in the Cell: Insights from the chemistry of metal ion receptors. Science 2003;300:931-936.
57. Davis AV, O'Halloran TV. A place for thioether chemistry in cellular copper ion recognition and trafficking. Nat Chem Biol 2008;4:148-151.
58. Pufahl RA, Singer CP, Peariso KL, Lin SJ, Schmidt PJ, Fahrni CJ, Cizewski Culotta V, Penner- Hahn JE, O'Halloran TV. Metal ion chaperone function of the soluble Cu(I) receptor Atx1. Science 1997;278:853-856.
59. Balatri E, Banci L, Bertini I, Cantini F, Ciofi-Baffoni S. Solution Structure of Sco1: A thioredoxin-like protein involved in cytochrome c Oxidase assembly. Structure 2003;11:1431-1443. (Pubitemid 37412425)
60. Xue Y, Davis AV, Balakrishnan G, Stasser JP, Staehlin BM, Focia P, Spiro TG, Penner-Hahn JE, O'Halloran TV. Cu(I) recognition via cation-pi and methionine interactions in CusF. Nat Chem Biol 2008;4:107-109.
61. Finney L, Vogt S, Fukai T, Glesne D. Copper and angiogenesis: Unraveling a relationship key to cancer progression. Clin Exp Pharmacol Physiol 2009;36:88-94.
62. Chen K, Yuldasheva S, Penner-Hahn JE, O'Halloran TV. An atypical linear Cu(I)-S2 center constitutes the high-affinity metal-sensing site in the CueR metalloregulatory protein. J Am Chem Soc 2003;125:12088-12089.
63. Chu F, Koomen JM, Kobayashi R, O'Brian CA. Identification of an inactivating cysteine switch in protein kinase Ce, a rational target for the design of protein kinase Ce-inhibitory cancer therapeutics. Cancer Res 2005;65:10478-10485. (Pubitemid 41743743)
64. La Fontaine S, Mercer JFB. Trafficking of the copper-ATPases, ATP7A and ATP7B: Role in copper homeostasis. Arch Biochem Biophys 2007;463:149-167.
65. Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. Physiol Rev 2007;87:1011-1046. (Pubitemid 47084675)
66. Lutsenko S, LeShane ES, Shinde U. Biochemical basis of regulation of human copper-transporting ATPases. Arch Biochem Biophys 2007;463:134-148. (Pubitemid 47030341)
67. Pierrel F, Cobine PA, Winge DR. Metal ion availability in mitochondria. BioMetals 2007;20:675-682.
68. Culotta VC, Yang M, O'Halloran TV. Activation of superoxide dismutases: Putting the metal to the pedal. Biochim Biophys Acta, Mol Cell Res 2006;1763:747-758. (Pubitemid 44189546)
69. de Bie P, Muller P, Wijmenga C, Klomp LWJ. Molecular pathogenesis of Wilson and Menkes diseases: Correlation of mutations with molecular defects and disease phenotypes. J Med Genet 2007;44:673-688. (Pubitemid 350161581)
70. Bertini I, Rosato A. Menkes disease. Cell Mol Life Sci 2008;65:89-91.
71. Menkes JH, Alter M, Steigleder GK, Weakley DR, Sung JH. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics 1962:764-779.
72. Danks DM, Campbell PE, Stevens BJ, Mayne V, Cartwright E. Menkes's kinky hair syndrome. An inherited defect in copper absorption with widespread effects. Pediatrics 1972;50:188-201.
73. Lazoff SG, Rybak JJ, Parker BR, Luzzatti L. Skeletal dysplasia, occipital horns, diarrhea and obstructive uropathy - a new hereditary syndrome. Birth Defects Orig Artic Ser 1975;11:71-74.
74. Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int 1999;41:423-429. (Pubitemid 29376990)
75. Shyamal DK, Ray K. Wilson's disease: an update. Nat Clin Pract Neurol 2006;2:482-493.
76. Riordan SM, Williams R. The Wilson's disease gene and phenotypic diversity. J Hepatol 2001;34:165-171. (Pubitemid 32102569)
77. Langner C, Denk H. Wilson disease. Virchows Arch 2004;445:111-118.
78. Huster D, Lutsenko S. Wilson disease: not just a copper disorder. Analysis of a Wilson disease model demonstrates the link between copper and lipid metabolism. Mol Biosyst 2007;3:816-824.
79. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993;3:7-13. (Pubitemid 23063281)
80. Chelly J, Tuemer Z, Toennesen T, Petterson A, Ishikawa-Brush Y, Tommerup N, Horn N, Monaco AP. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet 1993;3:14-19. (Pubitemid 23063282)
81. Mercer JFB, Livingston J, Hall B, Paynter JA, Begy C, Chandrasekharappa S, Lockhart P, Grimes A, Bhave M, Siemieniak D, Glover TW. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet 1993;3:20-25. (Pubitemid 23063283)
82. Das S, Levinson B, Vulpe C, Whitney S, Gitschier J, Packman S. Similar splicing mutations of the Menkes/mottled copper-transporting ATPase gene in occipital horn syndrome and the blotchy mouse. Am J Hum Genet 1995;56:570-576.
83. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327-337. (Pubitemid 23351302)
84. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993;5:344-350. (Pubitemid 23351304)
85. Petrukhin K, Fischer SG, Pirastu M, Tanzi RE, Chernov I, Devoto M, Brzustowicz LM, Cayanis E, Vitale E, Russo JJ, Matseoane D, Boukhgalter B, Wasco W, Figus AL, Loudianos J, Cao A, Sternlieb I, Evgrafov O, Parano E, Pavone L, Warburton D, Ott J, Penchaszadeh GK, Scheinberg IH, Gilliam TC. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993;5:338-343. (Pubitemid 23351303)
86. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993;197:271-277. (Pubitemid 23358907)
87. Katoh R, Takebayashi Y, Takenoshita S. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human solid carcinomas. Ann Thorac Cardiovasc Surg 2005;11:143-145. (Pubitemid 40403672)
88. Komatsu M, Sumizawa T, Mutoh M, Chen Z-S, Terada K, Furukawa T, Yang X-L, Gao H, Miura N, Sugiyama T, Akiyama S-I. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000;60:1312-1316. (Pubitemid 30152000)
89. Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H, Masuda R, Iwazaki M, Yamada S, Ueyama Y, Inoue H, Nakamura M. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 2008;20:265-270.
90. Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003;9:5853-5859. (Pubitemid 38018067)
91. Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che XF, Yamamoto M, Tsujikawa K, Kitazono M, Ishizawa T, Takeuchi T, Aikou T, Mercer JFB, Akiyama S, Furukawa T. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 2007;67:4860-4868.
92. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S-i. Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem 2008;15:3268-3278.
93. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006;106:1995-2044.
94. Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med 2000;223:39-46. (Pubitemid 30182655)
95. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003;37:1475-1492.
96. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: An update. Hepatology 2008;47:2089-2111. (Pubitemid 351945575)
97. Kodama H, Fujisawa C. Copper metabolism and inherited copper transport disorders: Molecular mechanisms, screening, and treatment. Metallomics 2009;1:42-52.
98. Goodyer ID, Jones EE, Monaco AP, Francis MJ. Characterization of the Menkes protein copper-binding domains and their role in copper-induced protein re-localization. Hum Mol Genet 1999;8:1473-1478.
99. Kaler SG. Menkes disease. Adv Pediatr 1994;41:263-304.
100. Horn N. Menkes' X-linked disease: Prenatal diagnosis and carrier detection. J Inherit Metab Dis 1983;6:59-62. (Pubitemid 14226354)
101. Gu YH, Kodama H, Murata Y, Mochizuki D, Yanagawa Y, Ushijima H, Shiba T, Lee CC. ATP7A gene mutations in 16 patients with Menkes disease and a patient with occipital horn syndrome. Am J Med Genet 2001;99:217-222. (Pubitemid 32206960)
102. Sarkar B. Treatment of Wilson and Menkes diseases. Chem Rev 1999;99:2535-2544.
103. Garnica A, Chan WY, Rennert O. Copper-histidine treatment of Menkes disease. J Pediatr 1994:336-338.
104. Sarkar B, Kruck TPA. Copper-amino acid complexes in human serum. Biochemistry of Copper, Proc Symp; Toronto, Canada: Univ. Toronto; 1966. pp 183-196.
105. Lau S-J, Kruck TPA, Sarkar B. Peptide molecule mimicking the copper(II) transport site of human serum albumin. Comparative study between the synthetic site and albumin. J Biol Chem 1974;249:5878-5884.
106. Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, Liew CJ, Sato S, Patronas N. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med 2008;358:605-614. (Pubitemid 351214287)
107. Reedy BJ, Blackburn NJ. Preparation and characterization of half-apo dopamine-beta-hydroxylase by selective removal of CuA. Identification of a sulfur ligand at the dioxygen binding site by EXAFS and FTIR spectroscopy. J Am Chem Soc 1994;116:1924-1931. (Pubitemid 2048914)
108. Kaler SG, Goldstein DS, Holmes C, Salerno JA, Gahl WA. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol 1993;33:171-175. (Pubitemid 23039925)
109. Mak CM, Lam C-W. Diagnosis of Wilson's Disease: A comprehensive review. Crit Rev Clin Lab Sci 2008;45:263-290.
110. Walshe JM. Wilson's disease; new oral therapy. Lancet 1956;270:25-26.
111. Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 2008;14:7526-7534.
112. Brewer GJ, Johnson VD, Dick RD, Hedera P, Fink JK, Kluin KJ. Treatment of wilson's disease with zinc. XVII: Treatment during pregnancy. Hepatology 2000;31:364-370.
113. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 2009;284:4749-4753.
114. Bayer TA, Wirths O, Majtenyi K, Hartmann T, Multhaup G, Beyreuther K, Czech C. Key factors in Alzheimer's disease: Beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001;11:1-11.
115. Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, Williamson NA, White AR, Hinds MG, Norton RS, Beyreuther K, Masters CL, Parker MW, Cappai R. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. J Biol Chem 2003;278:17401-17407.
116. Hesse L, Beher D, Masters CL, Multhaup G. The beta A4 amyloid precursor protein binding to copper. FEBS Lett 1994;349:109-116. (Pubitemid 2119590)
117. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
118. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
119. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
120. Deraeve C, Boldron C, Maraval A, Mazarguil H, Gornitzka H, Vendier L, Pitie M, Meunier B. Preparation and study of new poly-8-hydroxyquinoline chelators for an anti-Alzheimer strategy. Chem Eur J 2008;14:682-696.
121. Deraeve C, Pitie M, Mazarguil H, Meunier B. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents. New J Chem 2007;31:193-195. (Pubitemid 46227045)
122. Kutko KV, Kaplienko AI, Nikolova EP, Anders AG. EPR spectrum of copper orotate. Czech J Phys 2004;54:D591-D594.
123. Kessler H, Bayer TA, Bach D, Schneider-Axmann T, Supprian T, Herrmann W, Haber M, Multhaup G, Falkai P, Pajonk F-G. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial. J Neural Transm 2008;115:1181-1187.
124. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009;35:32-46.
125. Warburg O. The metabolism of tumors. London: Constable and Company Ltd; 1930.
126. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, Tsujinoue H, Nakatani T, Kishida H, Nakae D, Gomez DE, De Lorenzo MS, Tejera AM, Fukui H. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 2001;94:768-773. (Pubitemid 33032822)
127. Quesada AR, Munoz-Chapuli R, Medina MA. Anti-angiogenic drugs: From bench to clinical trials. Med Res Rev 2006;26:483-530. (Pubitemid 43939203)
128. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-860. (Pubitemid 40791824)
129. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
130. Ryan CJ, Wilding G. Angiogenesis inhibitors: New agents in cancer therapy. Drugs Aging 2000;17:249-255.
131. McAuslan BR, Reilly W. Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res 1980;130:147-157. (Pubitemid 11189744)
132. Gullino PM. Considerations on the mechanism of the angiogenic response. Anticancer Res 1986;6:153-158.
133. Hu G-F. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 1998;69:326-335. (Pubitemid 28227709)
134. Sen CK, Khanna S, Venojarvi M, Trikha P, Ellison EC, Hunt TK, Roy S. Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol 2002;282:H1821-H1827.
135. Nasulewicz A, Mazur A, Opolski A. Role of copper in tumor angiogenesis - clinical implications. J Trace Elem Med Biol 2004;18:1-8. (Pubitemid 39285958)
136. Moriguchi M, Nakajima T, Kimura H, Watanabe T, Takashima H, Mitsumoto Y, Katagishi T, Okanoue T, Kagawa K. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 2002;102:445-452. (Pubitemid 35315997)
137. Soncin F, Guitton J-D, Cartwright T, Badet J. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem Biophys Res Commun 1997;236:604-610. (Pubitemid 27384673)
138. Khan GN, Merajver SD. Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency. Curr Pharm Des 2007;13:3584-3590.
139. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: Lessons from treating Wilson's disease. Exp Biol Med 2001;226:665-673.
140. Teknos Theodoros N, Islam M, Arenberg Douglas A, Pan Q, Carskadon Shannon L, Abarbanell Aaron M, Marcus B, Paul S, Vandenberg Curtis D, Carron M, Nor Jacques E, Merajver Sofia D. The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2005;131:204-211. (Pubitemid 40349918)
141. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10. (Pubitemid 30064969)
142. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008;86:383-389; discussion 390. (Pubitemid 351978017)
143. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem 1994;269:7709-7718.
144. Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky SL, Darnell J. Molecular cell biology. 5th ed. New York: W.H. Freeman and CO; 2004. pp 66-72.
145. Marques AJ, Palanimurugan R, Matias AC, Ramos PC, Dohmen RJ. Catalytic mechanism and assembly of the proteasome. Chem Rev 2009;109:1509-1536.
146. Goldberg AL. Functions of the proteasome: The lysis at the end of the tunnel. Science 1995;268:522-523.
147. Dou QP, Smith David M, Daniel Kenyon G, Kazi A. Interruption of tumor cell cycle progression through proteasome inhibition: Implications for cancer therapy. Prog Cell Cycle Res 2003;5:441-446.
148. Richardson Paul G, Hideshima T, Anderson Kenneth C. Bortezomib (PS-341): A novel, first-inclass proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-369. (Pubitemid 37296062)
149. Adams J. The proteasome: Structure, function, and role in the cell. Cancer Treat Rev 2003;29:3-9.
150. Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 2003;95:845. (Pubitemid 36833869)
151. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493-500. (Pubitemid 34804773)
152. Dou QP, Goldfarb RH. Bortezomib millennium pharmaceuticals. Drugs 2002;5:828-834.
153. Fenteany G, Standaert RF, Reichard GA, Corey EJ, Schreiber SL. A beta -lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci USA 1994;91:3358-3362. (Pubitemid 24130236)
154. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062-1075.
155. Chen D, Dou QP. New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin Ther Targets 2008;12:739-748. (Pubitemid 351877302)
156. Cvek B, Milacic V, Taraba J, Dou QP. Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer Cells. J Med Chem 2008;51:6256-6258.
157. Ho Y-P, Au-Yeung SCF, To KKW. Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Med Res Rev 2003;23:633-655.
158. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003;7:481-489.
159. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000;59:1-8.
160. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm Chem Life Sci 2007;340:117-126. (Pubitemid 46953741)
161. Crim JA, Petering HG. The antitumor activity of Cu(II)KTS, the copper (II) chelate of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res 1967;27:1278-1285.
162. Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassian B, Colacino E, Fischer J, MacDonald S. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 2002;50:223-229. (Pubitemid 35013660)
163. Murugkar A, Unnikrishnan B, Padhye S, Bhonde R, Teat S, Triantafillou E, Sinn E. Hormone anchored metal complexes. 1. Synthesis, structure, spectroscopy and in vitro antitumor activity of testosterone acetate thiosemicarbazone and its metal complexes. Met-Based Drugs 1999;6:177-182.
164. Booth BA, Agrawal KC, Moore EC, Sartorelli AC. Alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone inhibitors of ribonucleoside diphosphate reductase. Cancer Res 1974;34:1308-1314.
165. Brockman RW, Thomson JR, Bell MJ, Skipper HE. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res 1956;16:167-170.
166. Scovill JP, Klayman DL, Franchino CF. 2-Acetylpyridine thiosemicarbazones. 4. Complexes with transition metals as antimalarial and antileukemic agents. J Med Chem 1982;25:1261-1264.
167. Easmon J, Heinisch G, Holzer W, Rosenwirth B. Synthesis and antiviral activity of thiosemicarbazone derivatives of pyridazinecarbaldehydes and alkyl pyridazinyl ketones. Arzneim-Forsch 1989;39:1196-1201. (Pubitemid 19255287)
168. West DX, Liberta AE, Padhye SB, Chikate RC, Sonawane PB, Kumbhar AS, Yerande RG. Thiosemicarbazone complexes of copper(II): Structural and biological studies. Coord Chem Rev 1993;123:49-71.
169. Easmon J, Puerstinger G, Heinisch G, Roth T, Fiebig HH, Holzer W, Jaeger W, Jenny M, Hofmann J. Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of 4N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J Med Chem 2001;44:2164-2171.
170. Belicchi Ferrari M, Capacchi S, Pelosi G, Reffo G, Tarasconi P, Albertini R, Pinelli S, Lunghi P. Synthesis, structural characterization and biological activity of helicin thiosemicarbazone monohydrate and a copper(II) complex of salicylaldehyde thiosemicarbazone. Inorg Chim Acta 1999;286:134-141.
171. Belicchi Ferrari M, Gasparri Fava G, Tarasconi P, Albertini R, Pinelli S, Starcich R. Synthesis, spectroscopic and structural characterization, and biological activity of aquachloro(pyridoxal thiosemicarbazone)copper(II) chloride. J Inorg Biochem 1994;53:13-25.
172. Belicchi Ferrari M, Bisceglie F, Leporati E, Pelosi G, Tarasconi P. Synthesis, solution chemistry, X-ray structure and biological activity of novel pyridoxal thiosemicarbazone derivatives. Bull Chem Soc Jpn 2002;75:781-788.
173. Belicchi Ferrari M, Fava GG, Leporati E, Pelosi G, Rossi R, Tarasconi P, Albertini R, Bonati A, Lunghi P, Pinelli S. Synthesis, characterization and biological activity of three copper(II) complexes with a modified nitrogenous base: 5-Formyluracil thiosemicarbazone. J Inorg Biochem 1998;70:145-154.
174. Baldini M, Belicchi-Ferrari M, Bisceglie F, Pelosi G, Pinelli S, Tarasconi P. Cu(II) complexes with heterocyclic substituted thiosemicarbazones: The case of 5-formyluracil. synthesis, characterization, X-ray structures, DNA interaction studies, and biological activity. Inorg Chem 2003;42:2049-2055.
175. Belicchi Ferrari M, Bisceglie F, Pelosi G, Tarasconi P, Albertini R, Bonati A, Lunghi P, Pinelli S. Synthesis, characterization, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes. J Inorg Biochem 2001;83:169-179.
176. Weder JE, Dillon CT, Hambley TW, Kennedy BJ, Lay PA, Biffin JR, Regtop HL, Davies NM. Copper complexes of non-steroidal anti-inflammatory drugs: An opportunity yet to be realized. Coord Chem Rev 2002;232:95-126.
177. Belicchi Ferrari M, Bisceglie F, Pelosi G, Sassi M, Tarasconi P, Cornia M, Capacchi S, Albertini R, Pinelli S. Synthesis, characterization and X-ray structures of new antiproliferative and proapoptotic natural aldehyde thiosemicarbazones and their nickel(II) and copper(II) complexes. J Inorg Biochem 2002;90:113-126.
178. Bisceglie F, Baldini M, Belicchi-Ferrari M, Buluggiu E, Careri M, Pelosi G, Pinelli S, Tarasconi P. Metal complexes of retinoid derivatives with antiproliferative activity: Synthesis, characterization and DNA interaction studies. Eur J Med Chem 2007;42:627-634.
179. Barve V, Ahmed F, Adsule S, Banerjee S, Kulkarni S, Katiyar P, Anson CE, Powell AK, Padhye S, Sarkar FH. Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells. J Med Chem 2006;49:3800-3808.
180. Zambre AP, Kulkarni VM, Padhye S, Sandur SK, Aggarwal BB. Novel curcumin analogs targeting TNF-induced NF-kB activation and proliferation in human leukemic KBM-5 cells. Bioorg Med Chem 2006;14:7196-7204. (Pubitemid 44403107)
181. Ambike V, Adsule S, Ahmed F, Wang Z, Afrasiabi Z, Sinn E, Sarkar F, Padhye S. Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. J Inorg Biochem 2007;101:1517-1524. (Pubitemid 47364803)
182. Saha DK, Padhye S, Padhye S. Targeting estrogen receptor sites in human breast cancer cell line T47D with copper conjugates of nonsteroidal antiinflammatory drug derivatives: Antiproliferative activity of ketoprofen derivative and its copper complex. Met-Based Drugs 2001;8:73-77. (Pubitemid 32674272)
183. Ahmed F, Adsule S, Ali AS, Banerjee S, Ali S, Kulkarni S, Padhye S, Sarkar FH. A novel copper complex of 3-benzoyl-alpha methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway. Int J Cancer 2007;120:734-742. (Pubitemid 46175391)
184. Adsule S, Barve V, Chen D, Ahmed F, Dou QP, Padhye S, Sarkar FH. Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J Med Chem 2006;49:7242-7246. (Pubitemid 44886011)
185. Milacic V, Chen D, Giovagnini L, Diez A, Fregona D, Dou QP. Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol Appl Pharmacol 2008;231:24-33.
186. Filomeni G, Cerchiaro G, Da Costa Ferreira AM, De Martino A, Pedersen JZ, Rotilio G, Ciriolo MR. Pro-apoptotic activity of novel isatin-Schiff base copper(II) complexes depends on oxidative stress induction and organelle-selective damage. J Biol Chem 2007;282:12010-12021. (Pubitemid 47100713)
187. Tamura H, Imai H, Kuwahara J, Sugiura Y. A new antitumor complex: bis(acetato)bis(imidazole) copper(II). J Am Chem Soc 1987;109:6870-6871. (Pubitemid 18036606)
188. Raptopoulou CP, Paschalidou S, Pantazaki AA, Terzis A, Perlepes SP, Lialiaris T, Bakalbassis EG, Mrozinski J, Kyriakidis DA. Bis(acetato)bis(1- methyl-4,5-diphenylimidazole)copper(II): Preparation, characterization, crystal structure, DNA strand breakage and cytogenetic effect. J Inorg Biochem 1998;71:15-27.
189. Habib NS, Rida SM, Badawey EA, Fahmy HT, Ghozlan HA. Synthesis and biological investigations of some novel thiazolylbenzimidazoles, and benzimidazolyl-thiazolo[4,5-d]pyrimidines. Pharmazie 1997;52:346-350.
190. Saczewski F, Dziemidowicz-Borys E, Bednarski PJ, Gruenert R, Gdaniec M, Tabin P. Synthesis, crystal structure and biological activities of copper(II) complexes with chelating bidentate 2-substituted benzimidazole ligands. J Inorg Biochem 2006;100:1389-1398.
191. Ohtsu H, Shimazaki Y, Odani A, Yamauchi O, Mori W, Itoh S, Fukuzumi S. Synthesis and characterization of imidazolate-bridged dinuclear complexes as active site models of Cu,Zn-SOD. J Am Chem Soc 2000;122:5733-5741. (Pubitemid 30432276)
192. Zhang H, Liu C-S, Bu X-H, Yang M. Synthesis, crystal structure, cytotoxic activity and DNA-binding properties of the copper(II) and zinc(II) complexes with 1-[3-(2-pyridyl)pyrazol-1-ylmethyl]naphthalene. J Inorg Biochem 2005;99:1119-1125.
193. Chen R, Liu C-S, Zhang H, Guo Y, Bu X-H, Yang M. Three new Cu(II) and Cd(II) complexes with 3-(2-pyridyl)pyrazole-based ligand: Syntheses, crystal structures, and evaluations for bioactivities. J Inorg Biochem 2007;101:412-421.
194. Dutta S, Padhye S, Ahmed F, Sarkar F. Pyridazolate-bridged dicopper (II) SOD mimics with enhanced antiproliferative activities against estrogen and androgen independent cancer cell lines. Inorg Chim Acta 2005;358:3617-3624. (Pubitemid 41265432)
195. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006;66:10425-10433. (Pubitemid 44799763)
196. Dallavalle F, Gaccioli F, Franchi-Gazzola R, Lanfranchi M, Marchio L, Pellinghelli MA, Tegoni M. Synthesis, molecular structure, solution equilibrium, and antiproliferative activity of thioxotriazoline and thioxotriazole complexes of copper(II) and palladium(II). J Inorg Biochem 2002;92:95-104.
197. Tardito S, Bussolati O, Gaccioli F, Gatti R, Guizzardi S, Uggeri J, Marchio L, Lanfranchi M, Franchi-Gazzola R. Non-apoptotic programmed cell death induced by a copper(II) complex in human fibrosarcoma cells. Histochem Cell Biol 2006;126:473-482. (Pubitemid 44435903)
198. Tardito S, Bussolati O, Maffini M, Tegoni M, Giannetto M, Dall'Asta V, Franchi-Gazzola R, Lanfranchi M, Pellinghelli MA, Mucchino C, Mori G, Marchio L. Thio-amido coordination in a thioxo-1,2,4-triazole copper(II) complex enhances non-apoptotic programmed cell death associated with copper accumulation and oxidative stress in human cancer cells. J Med Chem 2007;50:1916-1924.
199. Sigman DS, Graham DR, D'Aurora V, Stern AM. Oxygen-dependent cleavage of DNA by the 1,10-phenanthroline-cuprous complex. Inhibition of E. coli DNA polymerase I. J Biol Chem 1979;254:12269-12272. (Pubitemid 10138153)
200. Ranford JD, Sadler PJ, Tocher DA. Cytotoxicity and antiviral activity of transition-metal salicylato complexes and crystal structure of bis(diisopropylsalicylato)(1,10-phenanthroline)copper(II). J Chem Soc, Dalton Trans 1993:3393-3399.
201. Sigman DS, Landgraf R, Perrin DM, Pearson L. Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Met Ions Biol Syst 1996;33:485-513.
202. Thederahn TB, Kuwabara MD, Larsen TA, Sigman DS. Nuclease activity of 1,10-phenanthroline-copper: kinetic mechanism. J Am Chem Soc 1989;111:4941-4946.
203. Meijler MM, Zelenko O, Sigman DS. Chemical mechanism of DNA scission by (1,10-phenanthroline)copper. Carbonyl oxygen of 5-methylenefuranone is derived from water. J Am Chem Soc 1997;119:1135-1136.
204. Pitie M, Burrows CJ, Meunier B. Mechanisms of DNA cleavage by copper complexes of 3-clipphen and of its conjugate with a distamycin analogue. Nucleic Acids Res 2000;28:4856-4864. (Pubitemid 32014255)
205. Zhou H, Zheng C, Zou G, Tao D, Gong J. G1-phase specific apoptosis in liver carcinoma cell line induced by copper-1,10-phenanthroline. Int J Biochem Cell Biol 2002;34:678-684. (Pubitemid 34270720)
206. Cai X, Pan N, Zou G. Copper-1,10-phenanthroline-induced apoptosis in liver carcinoma Bel-7402 cells associates with copper overload, reactive oxygen species production, glutathione depletion and oxidative DNA damage. Biometals 2007;20:1-11. (Pubitemid 46292023)
207. Veal JM, Rill RL. Noncovalent DNA binding of bis(1,10-phenanthroline) copper(I) and related compounds. Biochemistry 1991;30:1132-1140.
208. Pitie M, Donnadieu B, Meunier B. Preparation of the new bis(phenanthroline) ligand "Clip-Phen" and evaluation of the nuclease activity of the corresponding copper complex. Inorg Chem 1998;37:3486-3489. (Pubitemid 128485863)
209. Pitie M, Boldron C, Gornitzka H, Hemmert C, Donnadieu B, Meunier B. DNA cleavage by copper complexes of 2- and 3-Clip-Phen derivatives. Eur J Inorg Chem 2003:528-540.
210. Pitie M, Sudres B, Meunier B. Dramatic increase of the DNA cleavage activity of Cu(Clip-Phen) by fixing the bridging linker on the C3 position of the phenanthroline units. Chem Commun 1998:2597-2598. (Pubitemid 28544860)
211. Pitie M, Meunier B. Preparation of a spermine conjugate of the bis-phenanthroline ligand Clip-Phen and evaluation of the corresponding copper complex. Bioconjugate Chem 1998;9:604-611. (Pubitemid 28437004)
212. de Hoog P, Boldron C, Gamez P, Sliedregt-Bol K, Roland I, Pitie M, Kiss R, Meunier B, Reedijk J. New approach for the preparation of efficient DNA cleaving agents: Ditopic copper-platinum complexes based on 3-clip-phen and cisplatin. J Med Chem 2007;50:3148-3152. (Pubitemid 47001257)
213. Bales BC, Kodama T, Weledji YN, Pitie M, Meunier B, Greenberg MM. Mechanistic studies on DNA damage by minor groove binding copper-phenanthroline conjugates. Nucleic Acids Res 2005;33:5371-5379. (Pubitemid 41487839)
214. 2=malonic acid) using human cancer cells. Cancer Lett 2007;247:224-233.
215. 2=salicylic acid; BZAH=benzoic acid; BZDH=benzimidazole and 5,6-DMBZDH=5,6-dimethylbenzimidazole). Polyhedron 2007;26:4073-4084.
216. Alemon-Medina R, Brena-Valle M, Munoz-Sanchez JL, Gracia-Mora MI, Ruiz-Azuara L. Induction of oxidative damage by copper-based antineoplastic drugs (Casiopeinas). Cancer Chemother Pharmacol 2007;60:219-228. (Pubitemid 46742537)
217. Trejo-Solis C, Palencia G, Zuniga S, Rodriguez-Ropon A, Osorio-Rico L, Luvia ST, Gracia-Mora I, Marquez-Rosado L, Sanchez A, Moreno-Garcia ME, Cruz A, Bravo-Gomez ME, Ruiz-Ramirez L, Rodriguez-Enriquez S, Sotelo J. Cas IIgly induces apoptosis in glioma C6 cells in vitro and in vivo through caspase-dependent and caspase-independent mechanisms. Neoplasia 2005;7:563-574. (Pubitemid 40967757)
218. Barcelo-Oliver M, Garcia-Raso A, Terron A, Molins E, Prieto MJ, Moreno V, Martinez J, Llado V, Lopez I, Gutierrez A, Escriba PV. Synthesis and mass spectroscopy kinetics of a novel ternary copper(II) complex with cytotoxic activity against cancer cells. J Inorg Biochem 2007;101:649-659. (Pubitemid 46357567)
219. Thati B, Noble A, Creaven BS, Walsh M, Kavanagh K, Egan DA. An in vitro investigation of the induction of apoptosis and modulation of cell cycle events in human cancer cells by bisphenanthroline-coumarin-6,7-dioxacetatocopper(II) complex. Chem Biol Interact 2007;168:143-158. (Pubitemid 46901068)
220. 2] (phen=phenanthroline, 4-Mecdoa=4-methylcoumarin-6, 7-dioxactetate), in human malignant cancer cells. Eur J Pharmacol 2007;569:16-28.
221. Rajendiran V, Karthik R, Palaniandavar M, Stoeckli-Evans H, Periasamy VS, Akbarsha MA, Srinag BS, Krishnamurthy H. Mixed-ligand Copper(II)-phenolate complexes: Effect of coligand on enhanced DNA and protein binding, DNA cleavage, and anticancer activity. Inorg Chem 2007;46:8208-8221.
222. Shaw CF. Gold-based therapeutic agents. Chem Rev 1999;99:2589-2600.
223. Berners-Price SJ, Johnson RK, Mirabelli CK, Faucette LF, McCabe FL, Sadler PJ. Copper(I) complexes with bidentate tertiary phosphine ligands: Solution chemistry and antitumor activity. Inorg Chem 1987;26:3383-3387.
224. Berners-Price SJ, Sadler PJ. Phosphines and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity. Structure & Bonding. Bioinorganic Chemistry. Berlin, Germany: Springer. Vol. 70; 1988. pp 27-102.
225. Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung CM, Mong SM, Sadler PJ, Crooke ST. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane] gold(I) chloride. Cancer Res 1986;46:5486-5493.
226. Hoke GD, Macia RA, Meunier PC, Bugelski PJ, Mirabelli CK, Rush GF, Matthews WD. In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit. Toxicol Appl Pharmacol 1989;100:293-306.
227. Adwankar MK, Wycliff C, Samuelson A. In vitro cytotoxic effect of new diphenylphosphinoethane-copper(I) complexes on human ovarian carcinoma cells. Indian J Exp Biol 1997;35:810-814.
228. Sanghamitra NJ, Phatak P, Das S, Samuelson AG, Somasundaram K. Mechanism of cytotoxicity of copper(I) complexes of 1,2-Bis(diphenylphosphino)ethane. J Med Chem 2005;48:977-985.
229. Marzano C, Pellei M, Alidori S, Brossa A, Gioia Lobbia G, Tisato F, Santini C. New copper(I) phosphane complexes of dihydrobis(3-nitro-1,2,4- triazolyl)borate ligand showing cytotoxic activity. J Inorg Biochem 2006;100:299-304.
230. Marzano C, Pellei M, Colavito D, Alidori S, Gioia Lobbia G, Gandin V, Tisato F, Santini C. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand. J Med Chem 2006;49:7317-7324.
231. Marzano C, Gandin V, Pellei M, Colavito D, Papini G, Gioia Lobbia G, DelGiudice E, Porchia M, Tisato F, Santini C. In vitro antitumor activity of the water soluble copper(I) complexes bearing the tris(hydroxymethyl)phosphine ligand. J Med Chem 2008;51:798-808.